YCBD Quote, Financials, Valuation and Earnings

Oragenics, Inc. has a net margin of -14.4% compared to cbdMD, Inc.'s net margin of --. cbdMD, Inc.'s return on equity of -57.5% beat Oragenics, Inc.'s return on equity of -509.23%.

cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 116.66%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 110.53%. Given that cbdMD, Inc. has higher upside potential than Oragenics, Inc., analysts believe cbdMD, Inc. is more attractive than Oragenics, Inc..

cbdMD, Inc. has a beta of 2.083, which suggesting that the stock is 108.347% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.

cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

cbdMD, Inc. quarterly revenues are $4.7M, which are larger than Oragenics, Inc. quarterly revenues of --. cbdMD, Inc.'s net income of -$680K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.24x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -14.4% compared to cbdMD, Inc.'s net margin of --. cbdMD, Inc.'s return on equity of -57.5% beat Palatin Technologies's return on equity of --.

cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 116.66%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than cbdMD, Inc., analysts believe Palatin Technologies is more attractive than cbdMD, Inc..

cbdMD, Inc. has a beta of 2.083, which suggesting that the stock is 108.347% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

cbdMD, Inc. quarterly revenues are $4.7M, which are larger than Palatin Technologies quarterly revenues of --. cbdMD, Inc.'s net income of -$680K is higher than Palatin Technologies's net income of --. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.24x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences, Inc. has a net margin of -14.4% compared to cbdMD, Inc.'s net margin of --. cbdMD, Inc.'s return on equity of -57.5% beat Cassava Sciences, Inc.'s return on equity of -86.98%.

cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 116.66%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 292.16%. Given that Cassava Sciences, Inc. has higher upside potential than cbdMD, Inc., analysts believe Cassava Sciences, Inc. is more attractive than cbdMD, Inc..

cbdMD, Inc. has a beta of 2.083, which suggesting that the stock is 108.347% more volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -1.000, suggesting its less volatile than the S&P 500 by 200.015%.

cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.

cbdMD, Inc. quarterly revenues are $4.7M, which are larger than Cassava Sciences, Inc. quarterly revenues of --. cbdMD, Inc.'s net income of -$680K is higher than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.24x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -14.4% compared to cbdMD, Inc.'s net margin of --. cbdMD, Inc.'s return on equity of -57.5% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 116.66%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3486.07%. Given that Theriva Biologics, Inc. has higher upside potential than cbdMD, Inc., analysts believe Theriva Biologics, Inc. is more attractive than cbdMD, Inc..

cbdMD, Inc. has a beta of 2.083, which suggesting that the stock is 108.347% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.

cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

cbdMD, Inc. quarterly revenues are $4.7M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. cbdMD, Inc.'s net income of -$680K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.24x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.